Tsubota Laboratory's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 66.45.
Tsubota Laboratory's Days Inventory for the
six
months ended in Mar. 2026 was 785.28.
Tsubota Laboratory's Days Payable for the
six
months ended in Mar. 2026 was 44.75.
Therefore, Tsubota Laboratory's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 806.98.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Tsubota Laboratory Cash Conversion Cycle Related Terms
Tsubota Laboratory Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Tsubota Laboratory's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4890 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Tsubota Laboratory's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsubota Laboratory Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Tsubota Laboratory's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Tsubota Laboratory's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsubota Laboratory (TSE:4890) has a Cash Conversion Cycle of 806.98 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Tsubota Laboratory and its competitors.
Is Tsubota Laboratory's Cash Conversion Cycle too high?
Tsubota Laboratory's current Cash Conversion Cycle is 806.98. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Tsubota Laboratory's value of 806.98 is 414.1% above this industry median. Overall, Tsubota Laboratory has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's Cash Conversion Cycle compare to ABT and SYK?
Tsubota Laboratory's Cash Conversion Cycle of 806.98 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Tsubota Laboratory's value of 806.98 is 414.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tsubota Laboratory's current Cash Conversion Cycle of 806.98 is 414.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Tsubota Laboratory and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsubota Laboratory's current Cash Conversion Cycle is 806.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円83.42, compared to a current price of 円244.00 — trading 192.5% above its estimated fair value. The current Cash Conversion Cycle is 806.98 and 414.1% above the Medical Devices & Instruments industry median of 156.96. Tsubota Laboratory's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current Cash Conversion Cycle is 806.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?
Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued.
The current stock price of 円244.00 is trading 192.5% above its estimated GF Value™ of 円83.42.
GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.
Key valuation signals for TSE:4890:
Cash Conversion Cycle: 806.98
GF Value™: 円83.42 vs. price of 円244.00 (192.5% above fair value)
Industry Position: 414.1% above the Medical Devices & Instruments median
No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
63GF Score
Get the complete analysis for TSE:4890
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4890 has been successfully added to your 
